Hypofractionated Radiation Therapy for Breast Cancer
Trial Summary
What is the purpose of this trial?
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Hypofractionated Radiation Therapy for Breast Cancer?
Research shows that hypofractionated radiation therapy (HFRT) is as effective and safe as traditional radiation therapy for early breast cancer, with fewer treatment sessions needed. Studies also indicate that HFRT is being increasingly used in real-world settings for both early and locally advanced breast cancer, suggesting its growing acceptance and effectiveness.12345
Is hypofractionated radiation therapy safe for breast cancer patients?
Research shows that hypofractionated radiation therapy (HFRT) is generally safe for breast cancer patients, with studies indicating it has similar safety levels to traditional radiation treatments. Some concerns about local control and toxicity exist, but overall, HFRT is becoming a standard treatment due to its safety and effectiveness.12456
How is hypofractionated radiation therapy different from other treatments for breast cancer?
Hypofractionated radiation therapy (HFRT) is unique because it delivers higher doses of radiation over fewer sessions compared to conventional radiation therapy, making the treatment period shorter. This approach is becoming a standard for breast cancer treatment due to its effectiveness and convenience.12367
Research Team
Matthew Poppe, MD
Principal Investigator
Huntsman Cancer Hospital, University of Utah
Eligibility Criteria
This trial is for women with stage IIa-IIIa breast cancer who've had a mastectomy. They must not be pregnant, have no history of certain other cancers or severe diseases, and agree to birth control if of childbearing potential. Participants should not have received prior chest radiation and must plan to start treatment within specific timeframes.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation Therapy
Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks
Hypofractionated Radiation Therapy
Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hypofractionated Radiation Therapy
Hypofractionated Radiation Therapy is already approved in United States, European Union, Canada for the following indications:
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Canadian Cancer Trials Group
Collaborator